Minerva Urology and Nephrology 2024 February;76(1):120-3

DOI: 10.23736/S2724-6051.23.05640-9

language: English

Metastatic de-novo renal cell carcinoma in the era of immune combinations: what can we learn from real-world data?

Giulio FRANCOLINI ^{1, 2}, Laura MARANDINO ^{2, 3}, Chiara CICCARESE ^{2, 4}, Alessio PECORARO ^{2, 5}, Daniele AMPARORE ^{2, 6} ✉, Riccardo CAMPI ^{2, 5}, European Association of Urology (EAU) Young Academic Urologists (YAU) Renal Cancer Working Group

¹ Unit of Radiation Oncology, Careggi University Hospital, Florence, Italy; ² European Association of Urology (EAU) Young Academic Urologists (YAU) Renal Cancer Working Group, Arnhem, the Netherlands; ³ Skin and Renal Unit, Royal Marsden NHS Foundation Trust, London, UK; ⁴ Unit of Medical Oncology, Comprehensive Cancer Center, IRCCS A. Gemelli University Polyclinic Foundation, Rome, Italy; ⁵ Unit of Urological Robotic Surgery and Renal Transplantation, Careggi University Hospital, University of Florence, Florence, Italy; ⁶ Department of Urology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Turin, Italy

HTML PDF

top of page

YOUR ACCOUNT

YOUR ORDERS

SHOPPING BASKET

HOW TO ORDER

YOUR SUBSCRIPTIONS

YOUR ARTICLES

YOUR EBOOKS

COUPON

ACCESSIBILITY

Minerva Urology and Nephrology 2024 February;76(1):120-3

Metastatic de-novo renal cell carcinoma in the era of immune combinations: what can we learn from real-world data?

Publication History

Cite this article as

European Association of Urology (EAU) Young Academic Urologists (YAU) Renal Cancer Working Group

Corresponding author e-mail

Share